HK-listed gold stocks jump as US economic fears boost bullion prices
On Wednesday, Piper Sandler initiated coverage of Monopar Therapeutics (NASDAQ:MNPR), assigning the biopharmaceutical company an Overweight rating and setting a price target of $76.00 per share. The stock has shown remarkable momentum, delivering an 11% return in the past week and an impressive 803% gain over the last year, according to InvestingPro data. The firm’s optimism is rooted in the potential of ALXN1840, Monopar’s treatment for Wilson disease, a rare and orphan condition that affects approximately 5,000 patients in the United States.
Monopar Therapeutics, currently valued at $209.6 million, acquired ALXN1840 from AstraZeneca (NASDAQ:AZN) in October 2024 after the latter discontinued the program. Piper Sandler’s coverage is based on the evaluation of data from the Phase 3 FoCus trial and additional mechanistic studies. InvestingPro analysis reveals the company maintains a healthy financial position with a current ratio of 5.41, indicating strong liquidity to support its development programs. The data suggests that ALXN1840 has a high chance of receiving FDA approval, especially considering the current unmet medical need for Wilson disease patients, particularly those with neurologic symptoms.
The company has announced plans to seek approval for ALXN1840 at the end of 2025 or early 2026. This move is seen as a significant step forward for Monopar, as the drug could address a critical gap in the treatment of this debilitating disease.
Additionally, Monopar Therapeutics is working on another therapy that targets uPAR for the treatment of solid tumors. Piper Sandler views this program as a potential upside in their valuation model, indicating that the company’s pipeline could contribute to future growth prospects.
The focus now turns to Monopar’s progress in developing these therapies and navigating the regulatory landscape to bring ALXN1840 to market. With the Overweight rating and a substantial price target, Piper Sandler signals confidence in Monopar’s strategic direction and the therapeutic promise of its product candidates. Two analysts have recently revised their earnings estimates upward, and investors should note the company’s upcoming earnings release on March 25, 2025. For deeper insights into Monopar’s financial health and additional analyst recommendations, consider exploring InvestingPro, which offers 11 more exclusive tips about this emerging biotech company.
In other recent news, Monopar Therapeutics Inc . has announced several key developments. The company has appointed Quan Vu as the new Chief Financial Officer, succeeding Karthik Radhakrishnan. Vu brings a wealth of experience from his previous roles at Ocugen (NASDAQ:OCGN), Inc. and 180 Life Sciences Corp. Additionally, Monopar has welcomed Lavina Talukdar to its Board of Directors, following the resignation of Michael J. Brown. Talukdar, who is currently with Moderna Inc (BMV:MRNA)., will also serve on multiple committees within the board.
Piper Sandler has initiated coverage on Monopar Therapeutics with an Overweight rating, setting a price target of $72.00. The firm’s analysts cite Monopar’s therapeutic pursuits, including radiotherapeutics and a small molecule for Wilson disease, as offering significant value. Furthermore, Monopar has announced the pricing of a new stock offering and a concurrent private placement of pre-funded warrants, aiming to raise $40 million in gross proceeds. The funds are intended for general corporate purposes, including research and development and clinical trials.
These recent developments underscore Monopar Therapeutics’ ongoing strategic initiatives and financial activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.